Neuromyelitis Optica
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Neuromyelitis Optica is a moderately active landscape with 44 programs across 25 companies. The most active players are Eli Lilly, Glaxo Dba Glaxosmithkline, Kenvue Brands. 8 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
64%
Small molecule
30 of 47 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 98% of 51 pipeline programs.
Analysis
Trial Status
53
clinical trials
Clinical Trials
Trial Activity
53 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)